低剂量丁丙诺啡在机械通气神经重症患者阿片及镇静药撤药中的启动:回顾性初步队列研究
本研究为回顾性匹配队列/病例对照初步研究,纳入神经重症监护单元接受肠外阿片并机械通气≥24小时的成人,比较低剂量丁丙诺啡启动(首8小时累计≤2mg且≥1次舌下给药,n=19)与未使用丁丙诺啡(n=18)的患者。丁丙诺啡组呼吸机天数更少(17.7±13.9 vs 29.3±13.9天,均差-11.65,95%CI -20.9至-2.4,p=0.008),中位拔管更早(16.0 vs 23.5天,p=0.021),启动后每日静脉阿片吗啡当量下降、目标RASS时间增加、持续镇静输注减少,且无丁丙诺啡相关沉淀性阿片戒断或呼吸抑制。结论为假设生成性,需前瞻性验证。
要点
- 神经重症机械通气≥24小时成人中,低剂量丁丙诺啡(首8小时累计≤2mg,≥1次舌下)与呼吸机天数减少相关(17.7±13.9 vs 29.3±13.9天,均差-11.65,95%CI -20.9至-2.4,p=0.008)。
- 丁丙诺啡组中位拔管时间更早(16.0 vs 23.5天,p=0.021),但ICU住院天数无差异(30.2±18.6 vs 31.8±14.9天,p=0.385)。
- 启动丁丙诺啡后每日静脉阿片吗啡当量从597.6±617.5 mg降至6.8±18.3 mg(p=0.001),目标RASS(-2至0)时间从63.9±27.8%增至81.6±22.0%(p=0.0001)。
- 持续镇静输注比例从73.7%降至31.6%(p=0.021);阿片戒断发生0/19(丁丙诺啡)vs 6/18(33.3%,对照,p=0.008),无丁丙诺啡相关沉淀性戒断或呼吸抑制。
- 小样本、回顾性、匹配设计、协同干预及残余混杂使结果仅属假设生成,需前瞻性验证。
适用人群与场景
- 神经重症监护单元(NCCU)成人患者,接受肠外阿片类药物且机械通气≥24小时。
诊断标准与关键阈值
- 低剂量丁丙诺啡启动定义:首8小时累计剂量≤2 mg,且至少1次舌下给药。
- 目标镇静范围为Richmond躁动-镇静评分(RASS)-2至0。
处置流程与药物剂量
- 在阿片/镇静药撤药策略中启动低剂量丁丙诺啡:首8小时累计≤2 mg,至少1次舌下给药(原文未提及后续剂量、频次或疗程)。
- 启动后监测每日静脉阿片吗啡当量(MME)、目标RASS时间比例、持续镇静输注暴露、阿片戒断及丁丙诺啡相关不良事件(沉淀性阿片戒断或呼吸抑制)。
红旗征与不能漏的情况
- 需警惕丁丙诺啡相关沉淀性阿片戒断(POW)或呼吸抑制;原文报告本队列无此类事件,但未给出具体处理措施。
- 阿片戒断:原文报告丁丙诺啡组0/19 vs 对照组6/18(33.3%),需监测。
研究设计与关键结果
- 研究类型:回顾性匹配队列/病例对照初步研究;样本量:丁丙诺啡组n=19,对照组n=18;单中心神经重症监护单元。
- 人群:成人接受肠外阿片且机械通气≥24小时;干预:低剂量丁丙诺啡启动(首8小时累计≤2 mg,≥1次舌下);对照:未使用丁丙诺啡,按人口学和诊断匹配。
- 主要结局:呼吸机天数17.7±13.9 vs 29.3±13.9天,均差-11.65(95%CI -20.9至-2.4),Cohen's d=0.84,p=0.008;中位拔管16.0 vs 23.5天,p=0.021。
- 次要结局:每日静脉MME从597.6±617.5降至6.8±18.3 mg(p=0.001);目标RASS时间从63.9±27.8%增至81.6±22.0%(p=0.0001);持续镇静输注从73.7%降至31.6%(p=0.021);ICU住院天数30.2±18.6 vs 31.8±14.9天(p=0.385)。
- 不良事件:无丁丙诺啡相关沉淀性戒断或呼吸抑制;阿片戒断0/19 vs 6/18(33.3%,p=0.008)。
证据类型、等级与局限
- 证据类型:回顾性匹配队列/病例对照初步研究(单中心)。
- 局限:样本量小、回顾性设计、协同干预、残余混杂,原文结论为假设生成性,需前瞻性验证。
对床旁实践的改变
- 在神经重症机械通气患者中,低剂量丁丙诺啡可作为阿片/镇静药撤药策略的一部分,可能减少呼吸机天数、阿片及镇静暴露并提高目标RASS达标时间。
- 适用人群:NCCU成人接受肠外阿片且机械通气≥24小时;原文未提及不适用人群。
- 常见陷阱:证据来自小样本回顾性研究,不能视为确切疗效;需警惕沉淀性阿片戒断和呼吸抑制,尽管本队列未发生。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Iatrogenic opioid dependence, withdrawal, and opioid accumulation can impede neurologic assessment and delay liberation from invasive mechanical ventilation (IMV) in neurocritical care. We evaluated whether low-dose buprenorphine (BUP) initiation was associated with improved sedation and ventilator outcomes.
METHODS: We conducted a retrospective matched cohort/case-control study of adults in the neurocritical care unit (NCCU) receiving parenteral opioids while on IMV ≥ 24 h. Patients receiving low-dose BUP initiation (≤ 2 mg cumulative in the first 8 h with ≥ 1 sublingual dose; n = 19) were matched by demographics and diagnosis to patients not receiving BUP (NO-BUP; n = 18). Outcomes included ventilator days/time to liberation, daily intravenous (IV) morphine milligram equivalents (MME), time-in-target range Richmond Agitation-Sedation Scale (RASS - 2 to 0), continuous sedative infusion exposure, opioid withdrawal, and BUP-attributable adverse events [precipitated opioid withdrawal (POW) or respiratory depression].
RESULTS: BUP patients had fewer ventilator days than NO-BUP patients (17.7 ± 13.9 vs. 29.3 ± 13.9 days; mean difference - 11.65, 95% CI - 20.9 to - 2.4; Cohen's d = 0.84; p = 0.008) and earlier median liberation (16.0 vs. 23.5 days; p = 0.021). After BUP initiation, daily IV MME decreased (597.6 ± 617.5 to 6.8 ± 18.3 mg; p = 0.001), target RASS time increased (63.9 ± 27.8% to 81.6 ± 22.0%; p = 0.0001), and continuous sedative infusions declined (73.7% to 31.6%; p = 0.021). No BUP patient experienced POW or respiratory depression temporally related to BUP; opioid withdrawal occurred in 0/19 BUP vs. 6/18 NO-BUP patients (33.3%; p = 0.008). The intensive care unit (ICU) length of stay was similar (30.2 ± 18.6 vs. 31.8 ± 14.9 days; p = 0.385).
CONCLUSIONS: In this pilot retrospective matched cohort study, low-dose BUP initiation as part of an opioid/sedative-weaning strategy was feasible and associated with higher documented time-in-target RASS, reduced opioid/sedative exposure, and faster IMV liberation without documented POW. Given the small sample size, co-interventions, retrospective design, and residual confounding, these findings should be considered hypothesis-generating and require prospective validation.
参考来源
- Carroll DK, King AM, Yakey B, et al. Low-Dose Buprenorphine Initiations During Opioid and Sedative Weaning in Mechanically Ventilated Neurocritical Care Patients: A Retrospective Pilot Cohort Study. Neurocrit Care. 2026. PMID: 42380718. doi:10.1007/s12028-026-02578-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。